Summary & Overview
HCPCS Level II J9371: Vincristine Sulfate Liposome Injection, 1 mg
HCPCS Level II code J9371 denotes the injection of vincristine sulfate liposome, 1 mg, an intravenous liposomal chemotherapy formulation used in oncology care. Nationally, accurate coding for specialty injectable oncology drugs like vincristine liposome is essential for claims processing, care coordination, and tracking utilization of high-cost therapies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the product, the typical sites of service where it is administered, and the scope of payers included in the analysis. The publication covers coding and billing benchmarks, typical reimbursement considerations, and any notable payer policy themes affecting coverage and administration of liposomal vincristine.
This summary equips billing managers, oncology practice administrators, and policy analysts with a clear understanding of what J9371 represents, which payers are included in comparative discussions, and what types of benchmark and policy information are addressed. Data not available in the input will be noted where relevant in detailed sections.
Billing Code Overview
HCPCS Level II code J9371 represents an injection of vincristine sulfate liposome, 1 mg. This code describes a parenteral chemotherapy agent formulated in liposomal form for intravenous administration.
Service Type: Drug administration (intravenous injectable chemotherapy)
Typical Site of Service: Hospital outpatient infusion center, oncology clinic, or other outpatient infusion settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric oncology patient with relapsed or refractory hematologic malignancy (most commonly acute lymphoblastic leukemia or certain lymphomas) being treated with vincristine sulfate liposome injection. The patient presents to an outpatient oncology infusion center or hospital outpatient infusion clinic for chemotherapy administration. Prior to infusion, the oncology clinician confirms diagnosis, weight-based dosing, baseline neurologic and hepatic function, venous access patency (peripheral IV or implanted port), and obtains informed consent. Pharmacy prepares J9371 (vincristine sulfate liposome, billed per 1 mg unit) under sterile chemotherapy compounding standards. The infusion nurse verifies the medication, dose, and patient identifiers, administers pre-medications as ordered, and delivers the infusion via IV push or short IV infusion per institutional protocol while monitoring vital signs and for extravasation. Post-infusion, the patient is observed for immediate adverse reactions and provided with follow-up instructions for neurotoxicity monitoring and symptom reporting. Documentation includes drug name, strength, units administered, lot number, route, start/stop times, site of service, and relevant diagnosis code(s).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | Use when reporting the professional component of a service if applicable for related services. |